SCI时时刷

search
New developments in pre-clinical models of ALS to guide translation
New developments in pre-clinical models of ALS to guide translation
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disorder, characterized by progressive and selective deg...
Cannabidiol and epilepsy
Cannabidiol and epilepsy
Epilepsy, a complex neurological disorder characterized by recurrent epileptic seizures, presents a considerable challenge...
Chapter One - AUD in perspective
Chapter One - AUD in perspective
Alcohol is a major cause of pre-mature death and individual suffering worldwide, and the importance of diagnosing and trea...
Chapter Two - Alcohol and the dopamine system
Chapter Two - Alcohol and the dopamine system
The mesolimbic dopamine pathway plays a major role in drug reinforcement and is likely involved also in the development of...
Chapter Three - GABAergic mechanisms in alcohol dependence
Chapter Three - GABAergic mechanisms in alcohol dependence
In 2014, it was estimated that brain diseases were responsible for 35% of Europe’s disease burden, with addictions having ...
Chapter Four - Current treatments of alcohol use disorder
Chapter Four - Current treatments of alcohol use disorder
Emerging treatments for alcohol dependence reveal an intricate interplay of neurobiological, psychological, and circumstan...
Chapter Five - Repurposing drugs for treatment of alcohol use disorder
Chapter Five - Repurposing drugs for treatment of alcohol use disorder
Repurposing drugs for the treatment of alcohol dependence involves the use of drugs that were initially developed for othe...
Chapter Six - Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Chapter Six - Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Julien Guiraud is employed by Vergio, Clichy, France and was employed by D&A Pharma until March 2022.Wim van den Brink...
Chapter Seven - Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
Chapter Seven - Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
While GABA is the main inhibitory transmitter in the brain, the last three decades have seen an increased appreciation of ...
Chapter Eight - Designing and testing treatments for alcohol use disorder
Chapter Eight - Designing and testing treatments for alcohol use disorder
Developing new treatments for AUD or personalizing existing treatments for AUD requires extensive consideration of researc...
Chapter Nine - Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Chapter Nine - Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Correct information of the actual alcohol intake is essential to assess the correlation with alcohol risk level consumptio...
GABAergic mechanisms in alcohol dependence
GABAergic mechanisms in alcohol dependence
In 2014, it was estimated that brain diseases were responsible for 35% of Europe’s disease burden, with addictions having ...
Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Correct information of the actual alcohol intake is essential to assess the correlation with alcohol risk level consumptio...
Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
While GABA is the main inhibitory transmitter in the brain, the last three decades have seen an increased appreciation of ...
Current treatments of alcohol use disorder
Current treatments of alcohol use disorder
Emerging treatments for alcohol dependence reveal an intricate interplay of neurobiological, psychological, and circumstan...
AUD in perspective
AUD in perspective
Available online 19 March 2024Author links open overlay panel, , , , , , , AbstractAlcohol is a major cause of pre-mature ...
Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
The development of new approaches for the treatment of alcohol dependence (AD) may improve patient outcomes. One very succ...
Alcohol and the dopamine system
Alcohol and the dopamine system
Available online 13 March 2024Author links open overlay panel, AbstractThe mesolimbic dopamine pathway plays a major role ...
Repurposing drugs for treatment of alcohol use disorder
Repurposing drugs for treatment of alcohol use disorder
Repurposing drugs for the treatment of alcohol dependence involves the use of drugs that were initially developed for othe...
Designing and testing treatments for alcohol use disorder
Designing and testing treatments for alcohol use disorder
Developing new treatments for AUD or personalizing existing treatments for AUD requires extensive consideration of researc...
Chapter Two - A general clinical overview of the non-motor symptoms in Parkinson’s disease: Neuropsychiatric symptoms
Chapter Two - A general clinical overview of the non-motor symptoms in Parkinson’s disease: Neuropsychiatric symptoms
The heterogeneity of non-motor features observed in people with Parkinson’s disease (PD) is often dominated by one or more...
Chapter Three - Insight gained from using animal models to study pain in Parkinson’s disease
Chapter Three - Insight gained from using animal models to study pain in Parkinson’s disease
Pain is one of the key non-motor symptoms experienced by a large proportion of people living with Parkinson’s disease (PD)...
Chapter Four - Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease
Chapter Four - Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease
Affective neuropsychiatric disorders such as depression, anxiety and apathy are among the most frequent non-motor symptoms...
Chapter Five - Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Chapter Five - Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, afflicting about 1% of people over 65 years ...
A general clinical overview of the non-motor symptoms in Parkinson’s disease: Neuropsychiatric symptoms
A general clinical overview of the non-motor symptoms in Parkinson’s disease: Neuropsychiatric symptoms
Available online 15 January 2024Author links open overlay panel, , , , AbstractThe heterogeneity of non-motor features obs...
Insight gained from using animal models to study pain in Parkinson’s disease
Insight gained from using animal models to study pain in Parkinson’s disease
As noted in Chapter 1, pain is one of the key non-motor symptoms experienced by more than half of those living with Parkin...